Goldman Sachs and UBS have emerged as the leading mergers and acquisitions (M&A) financial advisers in South America for 2024, in terms of deal value and volume, respectively, according to the latest league table from GlobalData, a data and analytics firm.

UBS analyst Brennan Hawken raised the firm’s price target on Goldman Sachs (GS) to $640 from $610 and keeps a Neutral rating on the shares. The

UBS Chief Executive Sergio Ermotti on Tuesday said it was currently premature for the Swiss bank to consider acquisitions as it continues to focus on the integration of Credit Suisse, which it bought in 2023.

Goldman Sachs (NYSE: GS) shares traded higher after reporting strong Q4 and full-year 2024 results. Revenue, EPS, and stock buybacks all beat expectations.

J.P. Morgan analyst Kian Abouhossein maintained a Buy rating on Goldman Sachs Group (GS – Research Report) today. The company’s shares opened

Goldman Sachs came third in this category with 179 deals, followed by UBS with 166 deals, and JP Morgan with 161 deals. In the deal value rankings, JP Morgan claimed the second spot by advising on ...

Mainland-listed stocks are likely to be higher at the end of 2025 thanks to improved corporate earnings and policy support from Beijing, UBS Group said, despite a shaky start to the year.

Analyst Ratings: In the last 15 days, Oppenheimer lowered Goldman Sachs stock price forecast from $677 to $639, UBS downgraded the stock to a Neutral rating with a price forecast of $610 ...

Goldman Sachs CEO David Solomon promoted a slew of top bankers on Tuesday to run the firm’s biggest business units, just days after the bank boss was awarded a pair of massive bonuses.

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share price rises for companies including Telix Pharmaceuticals, Clarity Pharmaceuticals and earlier-stage PYC Therapeutics.

While London South East do their best to maintain the high quality of the information displayed on this site, we cannot

UBS analysts, led by Joshua Chan, revised their price target for Bright Horizons (NYSE:BFAM) shares to $130.00, down from the previous $148.00, while maintaining a Neutral rating. Currently trading at $116.